Pfizer receives breakthrough therapy designation for breast cancer drug
The breakthrough therapy designation was based on preliminary Phase 2 trial, which demonstrated that women treated with the combination of palbociclib plus letrozole achieved a statistically significant improvement
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.